Trial Profile
Pharmacodynamics(PD) study of Arbekacin Sulfate in Epithelial Lining Fluid (ELF), an open-label study.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 18 May 2016
Price :
$35
*
At a glance
- Drugs Arbekacin (Primary)
- Indications Bacterial infections
- Focus Pharmacodynamics; Pharmacokinetics
- 12 Jun 2013 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan record.
- 12 May 2012 Planned end date (Nov 2012) added as reported by University Hospital Medical Information Network - Japan record.
- 02 Feb 2012 New trial record